Markets:

Overview

News

Currencies

International

Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

42.40 -1.65 (-3.75%)

Streaming Delayed Price Updated: 11:46 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection ↗

September 23, 2025

FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market.

Via Benzinga

Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues ↗

September 23, 2025

Via Stocktwits

Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug ↗

September 23, 2025

Shares tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug.

Via Investor's Business Daily

Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

September 23, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 23, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

September 23, 2025

From Scholar Rock

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 22, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Monday? ↗

September 22, 2025

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Why Scholar Rock Stock Bounced Higher on Monday ↗

September 15, 2025

One pundit believes the share price could rise in excess of 50%.

Via The Motley Fool

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 12, 2025

From Scholar Rock

Via Business Wire

How Do Investors Really Feel About Scholar Rock Holding? ↗

September 08, 2025

Via Benzinga

Here's How Much $1000 Invested In Scholar Rock Holding 5 Years Ago Would Be Worth Today ↗

September 01, 2025

Via Benzinga

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 15, 2025

From Scholar Rock

Via Business Wire

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

August 14, 2025

From Scholar Rock

Via Business Wire

Here's How Much You Would Have Made Owning Scholar Rock Holding Stock In The Last 5 Years ↗

August 07, 2025

Via Benzinga

Why Scholar Rock Stock Wilted on Wednesday ↗

August 06, 2025

The market was hoping the company could better contain its losses.

Via The Motley Fool

Scholar Rock (SRRK) Q2 Loss Widens 63% ↗

August 06, 2025

Via The Motley Fool

Scholar Rock Holding Corp (NASDAQ:SRRK) Reports Q2 2025 Wider Loss but Market Shows Optimism Ahead of Key FDA Decision ↗

August 06, 2025

Scholar Rock reports Q2 2025 loss of $0.98 per share but gains investor optimism ahead of FDA decision for apitegromab in SMA. Cash runway extends to 2027.

Via Chartmill

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

August 06, 2025

From Scholar Rock

Via Business Wire

Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year ↗

July 23, 2025

Via The Motley Fool

Topics Regulatory Compliance

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

July 21, 2025

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025

From Scholar Rock

Via Business Wire

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

June 23, 2025

From Scholar Rock

Via Business Wire

Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss ↗

June 18, 2025

Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.

Via Stocktwits

Topics Death

Why Scholar Rock Shares Are Soaring Today ↗

June 18, 2025

Via The Motley Fool

Topics Stocks

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study ↗

June 18, 2025

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial.

Via Benzinga

Which stocks are gapping on Wednesday? ↗

June 18, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

June 18, 2025

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

June 18, 2025

From Scholar Rock

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.